Targeted therapy in lymphoma

Journal of Hematology and Oncology

Volumn 3, Issue , 2010, Pages

  Johnston, Patrick B ^a   Yuan, Ruirong ^b,c   Cavalli, Franco ^d   Witzig, Thomas E ^a  

^a MAYO CLINIC   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^d ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; GEMCITABINE; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PANOBINOSTAT; PREDNISONE; RAPAMYCIN; RIDAFOROLIMUS; RITUXIMAB; ROMIDEPSIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE DERIVATIVE; VALPROIC ACID; VINCRISTINE; VORINOSTAT; BORONIC ACID DERIVATIVE; DRUG DERIVATIVE; PYRAZINE DERIVATIVE;

ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; CANCER FATIGUE; CANCER INHIBITION; CANCER SURVIVAL; CLINICAL PATHWAY; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FOLLICULAR LYMPHOMA; GASTROINTESTINAL SYMPTOM; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LEUKOPENIA; LYMPHOCYTOMA; LYMPHOMA; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PERIPHERAL NEUROPATHY; PLEURA EFFUSION; REVIEW; RNA TRANSLATION; SIDE EFFECT; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA; WEIGHT REDUCTION; METHODOLOGY; SURVIVAL;

BORONIC ACIDS; HUMANS; LYMPHOMA; MOLECULAR TARGETED THERAPY; PYRAZINES; SIGNAL TRANSDUCTION; SIROLIMUS; SURVIVAL ANALYSIS;

EID: 78549233720     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-3-45     Document Type: Review

References (48)

1. Cancer statistics, 2010. A Jemal R Siegel J Xu E Ward, CA Cancer J Clin 2010 60 277 300 10.3322/caac.20073 20610543
2. Estimates of the cancer incidence and mortality in Europe in 2006. J Ferlay P Autier M Boniol M Heanue M Colombet P Boyle, Ann Oncol 2007 18 581 592 10.1093/annonc/mdl498 17287242
3. Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: A review of the evidence. F Morschhauser M Dreyling A Rohatiner F Hagemeister A Bischof Delaloyee, The Oncologist 2009 14 Suppl 2 17 29 10.1634/theoncologist.2009-S2-17 19819921
4. Mantle cell lymphoma. SA Pileri B Falini, Haematologica 2009 94 1488 1492 10.3324/haematol.2009.013359 19880776
5. New targets for lymphoma treatment. PWM Johnson, Ann Oncol 2008 19 Suppl 4 v56 iv59 10.1093/annonc/mdn198 18519406
6. Proteasome inhibitors: a novel class of potent and effective antitumor agents. J Adams VJ Palombella EA Sausville J Johnson A Destree DD Lazarus J Maas CS Pien S Prakash PJ Elliott, Cancer Res 1999 59 2615 2622 10363983
7. New targets for the treatment of follicular lymphoma. N Tageja P Padheye P Dandawate A Al-Katib RM Mohammad, J Hematol Oncol 2009 2 50 10.1186/1756-8722-2-50 20030851
8. Exploiting the mammalian target of rapamycin pathway in hematologic malignancies. JK Altman LC Platanias, Curr Opin Hematol 2008 15 88 94 10.1097/MOH.0b013e3282f3deaa 18300753
9. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. R Yuan A Kay WJ Berg D Lebwohl, J Hematol Oncol 2009 2 45 10.1186/1756-8722-2-45 19860903
10. Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. DT Teachey SA Grupp VI Brown, Br J Haematol 2009 145 569 580 10.1111/j.1365-2141.2009.07657.x 19344392
11. Lenalidomide for the treatment of B-cell malignancies. AA Chanan-Khan BD Cheson, J Clin Oncol 2008 26 1544 1552 10.1200/JCO.2007.14.5367 18285605
12. Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND. 182-185. R Buckstein RM Meyer L Seymour J Biagi H Mackay S Laurie E Eisenhauer, Curr Oncol 2007 14 154 161 10.3747/co.2007.132 17710208
13. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway. T Kurosu M Ohki N Wu H Kagechika O Miura, Cancer Res 2009 69 3927 3936 10.1158/0008-5472.CAN-08-2978 19366808
14. Histone deacetylase inhibitors as anti-neoplastic agents. N Batty GG Malouf JP Issa, Cancer Lett 2009 280 192 200 10.1016/j.canlet.2009.03.013 19345475
15. Proteasome inhibition as a new therapeutic principle in hematological malignancies. CS Mitsiades N Mitsiades T Hideshima PG Richardson KC Anderson, Curr Drug Targets 2006 7 1341 1347 10.2174/138945006778559247 17073596
16. Velcade Prescribing Information. Millennium Pharmaceuticals, Inc, 2009 http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/021602s019s020lbl.pdf
17. Lenalidomide: a novel anticancer drug with multiple modalities. C Galustian A Dalgleish, Expert Opin Pharmacother 2009 10 125 133 10.1517/14656560802627903 19236186
18. HDAC inhibitor-based therapies and haematological malignancy. L Stimson V Wood O Khan S Fotheringham NB La Thangue, Ann Oncol 2009 20 1293 1302 10.1093/annonc/mdn792 19515748
19. Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma. M Dickinson D Ritchie DJ DeAngelo A Spencer OG Ottmann T Fischer KN Bhalla A Liu K Parker JW Scott M Bishton HM Prince, Br J Haematol 2009 147 97 101 10.1111/j.1365-2141.2009.07837. x 19663825
20. VcR-CVAD produces a high response rate in untreated mantle cell lymphoma: a phase II study from the Wisconsin Oncology Network. B Kahl J Chang J Eickhoff L Gilbert E Rogers J Werndli M Huie T McFarland M Volk JH Blank N Callander W Longo C Peterson, Blood 2008 112 Suppl 1 bstract 265
21. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. OA O'Connor J Wright C Moskowitz J Muzzy B MacGregor-Cortelli M Stubblefield D Straus C Portlock P Hamlin E Choi O Dumetrescu D Esseltine E Trehu J Adams D Schenkein AD Zelenetz, J Clin Oncol 2005 23 676 684 10.1200/JCO.2005.02.050 15613699
22. Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. J Gerecitano C Portlock C Moskowitz P Hamlin D Straus AD Zelenetz Z Zhang O Dumitrescu D Sarasohn D Lin J Pappanicholaou BM Cortelli E Neylon R Hamelers J Wright OA O'Connor, Br J Haematol 2009 146 652 655 10.1111/j.1365-2141.2009.07775.x 19624539
23. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. A Goy A Younes P McLaughlin B Pro JE Romaguera F Hagemeister L Fayad NH Dang F Samaniego M Wang K Broglio B Samuels F Gilles AH Sarris S Hart E Trehu D Schenkein F Cabanillas AM Rodriguez, J Clin Oncol 2005 23 667 675 10.1200/JCO.2005.03.108 15613697
24. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. SJ Strauss L Maharaj S Hoare PW Johnson JA Radford S Vinnecombe L Millard A Rohatiner A Boral E Trehu D Schenkein F Balkwill SP Joel TA Lister, J Clin Oncol 2006 24 2105 2112 10.1200/JCO.2005.04. 6789 16606971
25. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. RI Fisher SH Bernstein BS Kahl B Djulbegovic MJ Robertson S de Vos E Epner A Krishnan JP Leonard S Lonial EA Stadtmauer OA O'Connor H Shi AL Boral A Goy, J Clin Oncol 2006 24 4867 4874 10.1200/JCO.2006.07.9665 17001068
26. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. A Goy SH Bernstein BS Kahl B Djulbegovic MJ Robertson S de Vos E Epner A Krishnan JP Leonard S Lonial S Nasta OA O'Connor H Shi AL Boral RI Fisher, Ann Oncol 2009 20 520 525 10.1093/annonc/mdn656 19074748
27. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. A Belch CT Kouroukis M Crump L Sehn RD Gascoyne R Klasa J Powers J Wright EA Eisenhauer, Ann Oncol 2007 18 116 121 10.1093/annonc/mdl316 16971665
28. Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial. OA O'Connor C Moskowitz C Portlock P Hamlin D Straus O Dumitrescu D Sarasohn M Gonen J Butos E Neylon R Hamelers B Mac-Gregor Cortelli S Blumel AD Zelenetz L Gordon JJ Wright J Vose B Cooper J Winter, Br J Haematol 2009 145 34 39 10.1111/j.1365-2141.2008.07466.x 19220284
29. A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study. O Weigert E Weidmann R Mueck M Bentz C von Schilling R Rohrberg K Jentsch-Ullrich W Hiddemann M Dreyling, Leuk Lymphoma 2009 50 716 722 10.1080/10428190902856790 19347767
30. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. K Dunleavy S Pittaluga MS Czuczman SS Dave G Wright N Grant M Shovlin ES Jaffe JE Janik LM Staudt WH Wilson, Blood 2009 113 6069 6076 10.1182/blood-2009-01-199679 19380866
31. Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT00148018). S Trelle O Sezer R Naumann M Rummel U Keller A Engert P Borchmann, Haematologica 2007 92 568 569 10.3324/haematol.10797 17488673
32. Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206. KA Blum JL Johnson D Niedzwiecki GP Canellos BD Cheson NL Bartlett, Leuk Lymphoma 2007 48 1313 1319 10.1080/10428190701411458 17613759
33. Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma. JH Mendler J Kelly S Voci D Marquis L Rich RM Rossi SH Bernstein CT Jordan J Liesveld RI Fisher JW Friedberg, Ann Oncol 2008 19 1759 1764 10.1093/annonc/mdn365 18504251
34. Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma. O Weigert A Pastore M Rieken N Lang W Hiddemann M Dreyling, Leukemia 2007 21 524 528 10.1038/sj.leu.2404511 17268531
35. Phase I trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. RR Furman P Martin J Ruan YK Cheung JM Vose AS Lacasce R Elstrom M Coleman JP Leonard, Cancer 2010 27
36. A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas. F Jundt N Raetzel C Müller CF Calkhoven K Kley S Mathas A Lietz A Leutz B Dörken, Blood 2005 106 1801 1807 10.1182/blood-2004-11-4513 15886325
37. Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. VY Yazbeck D Buglio GV Georgakis Y Li E Iwado JE Romaguera S Kondo A Younes, Exp Hematol 2008 36 443 450 10.1016/j.exphem.2007.12.008 18343280
38. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. TE Witzig CB Reeder BR LaPlant PB Johnston IN Micallef LF Porrata SM Ansell JP Colgan E Jacobsen I Ghobrial TM Habermann, Leukemia
39. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. KW Yee Z Zeng M Konopleva S Verstovsek F Ravandi A Ferrajoli D Thomas W Wierda E Apostolidou M Albitar S O'Brien M Andreeff FJ Giles, Clin Cancer Res 2006 12 5165 5173 10.1158/1078-0432.CCR-06-0764 16951235
40. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. TE Witzig SM Geyer I Ghobrial DJ Inwards R Fonseca P Kurtin SM Ansell R Luyun PJ Flynn RF Morton SR Dakhil H Gross SH Kaufmann, J Clin Oncol 2005 23 5347 5356 10.1200/JCO.2005.13.466 15983389
41. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. SM Ansell DJ Inwards KM Rowland Jr PJ Flynn RF Morton DF Moore Jr SH Kaufmann I Ghobrial PJ Kurtin M Maurer C Allmer TE Witzig, Cancer 2008 113 508 514 10.1002/cncr.23580 18543327
42. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. G Hess R Herbrecht J Romaguera G Verhoef M Crump C Gisselbrecht A Laurell F Offner A Strahs A Berkenblit O Hanushevsky J Clancy B Hewes L Moore B Coiffier, J Clin Oncol 2009 27 3822 3829 10.1200/JCO.2008.20.7977 19581539
43. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. DA Rizzieri E Feldman JF Dipersio N Gabrail W Stock R Strair VM Rivera M Albitar CL Bedrosian FJ Giles, Clin Cancer Res 2008 14 2756 2762 10.1158/1078-0432.CCR-07-1372 18451242
44. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. IM Ghobrial M Gertz B LaPlant J Camoriano S Hayman M Lacy S Chuma B Harris R Leduc M Rourke SM Ansell D DeAngelo A Dispenzieri L Bergsagel C Reeder KC Anderson PG Richardson SP Treon TE Witzig, J Clin Oncol 2010 28 1408 1414 10.1200/JCO.2009.24.0994 20142598
45. A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. PB Johnston DJ Inwards JP Colgan BR LaPlant BF Kabat TM Habermann IN Micallef LF Porrata SM Ansell CB Reeder V Roy TE Witzig, Am J Hematol 2010 85 320 324 20229590
46. Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. P Armand S Gannamaneni HT Kim CS Cutler VT Ho J Koreth EP Alyea AS LaCasce ED Jacobsen DC Fisher JR Brown GP Canellos AS Freedman RJ Soiffer JH Antin, J Clin Oncol 2008 26 5767 5774 10.1200/JCO.2008.17.7279 19001324
47. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. PH Wiernik IS Lossos JM Tuscano G Justice JM Vose CE Cole W Lam K McBride K Wride D Pietronigro K Takeshita A Ervin-Haynes JB Zeldis TM Habermann, J Clin Oncol 2008 26 4952 4957 10.1200/JCO.2007.15.3429 18606983
48. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. TM Habermann IS Lossos G Justice JM Vose PH Wiernik K McBride K Wride A Ervin-Haynes K Takeshita D Pietronigro JB Zeldis JM Tuscano, Br J Haematol 2009 145 344 349 10.1111/j.1365-2141.2009.07626.x 19245430